Ken Pastor

GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada.

CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal.

CTI Life Sciences Fund provides life science related services. The private company is based in Montréal, Canada. The Canadian company was founded in 2006 by Kenneth Pastor.

CTI Capital Securities, Inc. (CTI) is the brokerage subsidiary of CTI Capital Groupe, Inc. The firm is headquartered in Montréal and was founded in 1987. CTI provides brokerage services in the fixed-income, money market and stock markets. Their fixed-income research seeks to identify the optimal strategy for the term, duration and tactical opportunities between different sectors of the market. Their equity research focuses on continuous global monitoring of the Canadian stock market.

Founded in 1987, CTI Fond Mutuels is a mutual fund manager headquartered in Montreal, Quebec. The firm is a subsidiary of CTI Capital, Inc. They manage some of the CTI mutual funds.